Program Type: Midwest CEPAC

Sneha Dave, BA


 [PR1]Confirming Sneha’s credentials – Monica sent her an email

Multiple Myeloma

Apr 2021 | Assessment

The Midwest CEPAC unanimously determined the evidence is adequate to demonstrate that CAR-T treatments ide-cel and cilta-cel both provide a net health benefit when compared to usual care; despite these benefits, for ide-cel, the only CAR-T agent having received FDA approval at this time, a majority of panelists voted that it represents “low” long-term value […]